Literature DB >> 27566380

Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis.

Shun Kondoh1, Hirofumi Chiba2, Hirotaka Nishikiori3, Yasuaki Umeda4, Koji Kuronuma5, Mitsuo Otsuka6, Gen Yamada7, Hirofumi Ohnishi8, Mitsuru Mori9, Yasuhiro Kondoh10, Hiroyuki Taniguchi11, Sakae Homma12, Hiroki Takahashi13.   

Abstract

BACKGROUND: The clinical course of idiopathic pulmonary fibrosis (IPF) shows great inter-individual differences. It is important to standardize the severity classification to accurately evaluate each patient׳s prognosis. In Japan, an original severity classification (the Japanese disease severity classification, JSC) is used. In the United States, the new multidimensional index and staging system (the GAP model) has been proposed. The objective of this study was to evaluate the model performance for the prediction of mortality risk of the JSC and GAP models using a large cohort of Japanese patients with IPF.
METHODS: This is a retrospective cohort study including 326 patients with IPF in the Hokkaido prefecture from 2003 to 2007. We obtained the survival curves of each stage of the GAP and JSC models to perform a comparison. In the GAP model, the prognostic value for mortality risk of Japanese patients was also evaluated.
RESULTS: In the JSC, patient prognoses were roughly divided into two groups, mild cases (Stages I and II) and severe cases (Stages III and IV). In the GAP model, there was no significant difference in survival between Stages II and III, and the mortality rates in the patients classified into the GAP Stages I and II were underestimated.
CONCLUSIONS: It is difficult to predict accurate prognosis of IPF using the JSC and the GAP models. A re-examination of the variables from the two models is required, as well as an evaluation of the prognostic value to revise the severity classification for Japanese patients with IPF.
Copyright © 2016 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GAP model; Idiopathic pulmonary fibrosis; Japanese disease severity classification; Validation

Mesh:

Year:  2016        PMID: 27566380     DOI: 10.1016/j.resinv.2016.02.009

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  10 in total

1.  The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease.

Authors:  Rebeccah M Brusca; Iago Pinal-Fernandez; Kevin Psoter; Julie J Paik; Jemima Albayda; Christopher Mecoli; Eleni Tiniakou; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff; Cheilonda Johnson
Journal:  Respir Med       Date:  2019-02-21       Impact factor: 3.415

2.  Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.

Authors:  Aya Fukuizumi; Yuji Minegishi; Miwako Omori; Kenichiro Atsumi; Natsuki Takano; Kakeru Hisakane; Satoshi Takahashi; Kenichi Kobayashi; Teppei Sugano; Susumu Takeuchi; Rintaro Noro; Masahiro Seike; Kaoru Kubota; Arata Azuma; Akihiko Gemma
Journal:  Int J Clin Oncol       Date:  2019-07-27       Impact factor: 3.402

3.  Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Takayuki Takeda; Yusuke Kunimatsu; Nozomi Tani; Izumi Hashimoto; Yuri Kurono; Kazuki Hirose
Journal:  J Clin Med       Date:  2020-03-11       Impact factor: 4.241

4.  Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Kazutaka Takehara; Yasuhiko Koga; Yoshimasa Hachisu; Mitsuyoshi Utsugi; Yuri Sawada; Yasuyuki Saito; Seishi Yoshimi; Masakiyo Yatomi; Yuki Shin; Ikuo Wakamatsu; Kazue Umetsu; Shunichi Kouno; Junichi Nakagawa; Noriaki Sunaga; Toshitaka Maeno; Takeshi Hisada
Journal:  Cells       Date:  2022-01-02       Impact factor: 6.600

5.  The 1-minute sit-to-stand test to detect desaturation during 6-minute walk test in interstitial lung disease.

Authors:  Keiji Oishi; Kazuto Matsunaga; Maki Asami-Noyama; Tasuku Yamamoto; Yukari Hisamoto; Tetsuya Fujii; Misa Harada; Junki Suizu; Keita Murakawa; Ayumi Chikumoto; Kazuki Matsuda; Haruka Kanesada; Yujiro Kikuchi; Kazuki Hamada; Sho Uehara; Ryo Suetake; Syuichiro Ohata; Yoriyuki Murata; Yoshikazu Yamaji; Kenji Sakamoto; Kosuke Ito; Hisayuki Osoreda; Nobutaka Edakuni; Tomoyuki Kakugawa; Tsunahiko Hirano; Masafumi Yano
Journal:  NPJ Prim Care Respir Med       Date:  2022-01-27       Impact factor: 2.871

6.  Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.

Authors:  Keishi Sugino; Hirotaka Ono; Natsumi Watanabe; Masahiro Ando; Eiyasu Tsuboi; Sakae Homma; Kazuma Kishi
Journal:  BMC Pulm Med       Date:  2021-07-10       Impact factor: 3.317

7.  Impact of mediastinal lymph node enlargement on the prognosis of idiopathic pulmonary fibrosis.

Authors:  Sooim Sin; Kyung Hee Lee; Jee Hye Hur; Sang-Hoon Lee; Yeon Joo Lee; Young-Jae Cho; Ho Il Yoon; Jae Ho Lee; Choon Taek Lee; Jong Sun Park
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

8.  Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients.

Authors:  Tejaswini Kulkarni; Kaiyu Yuan; Thi K Tran-Nguyen; Young-Il Kim; Joao A de Andrade; Tracy Luckhardt; Vincent G Valentine; Daniel J Kass; Steven R Duncan
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

9.  Analysis of nocturnal desaturation waveforms using algorithms in patients with idiopathic pulmonary fibrosis.

Authors:  Yuichiro Yasuda; Tatsuya Nagano; Shintaro Izumi; Mina Yasuda; Kosuke Tsuruno; Kazunori Tobino; Kyosuke Nakata; Kayoko Okamura; Teruaki Nishiuma; Kiyonobu Takatsuki; Yasuhiro Funada; Hisashi Ohnishi; Masatsugu Yamamoto; Yoshihiro Nishimura; Kazuyuki Kobayashi
Journal:  Sleep Breath       Date:  2021-08-21       Impact factor: 2.655

Review 10.  Global incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Toby M Maher; Elisabeth Bendstrup; Louis Dron; Jonathan Langley; Gerald Smith; Javaria Mona Khalid; Haridarshan Patel; Michael Kreuter
Journal:  Respir Res       Date:  2021-07-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.